Low-Grade Serous Carcinoma – The Clinical Challenge

Crossmark: check for updates

Authors

  • Khadija Warfa Gynecologic Oncology Fellow, University of Calgary & Tom Baker Cancer Centre, 1331 29 Street NW, Calgary Alberta, T2N 4N2, Canada
  • Martin Köbel Gynecologic Pathologist, Calgary laboratory services, University of Calgary, Calgary, Alberta, Canada
  • Prafull Ghatage Gynecologic Oncologist, Division of Gynecologic Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada
  • Gregg Nelson Gynecologic Oncologist, Division of Gynecologic Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada

DOI:

https://doi.org/10.17140/GOROJ-2-108

Keywords:

Low-grade serous carcinoma, High-grade serous carcinoma, Ovarian cancer

Abstract

Low-grade serous carcinoma is one of the five major histological types of ovarian carcinoma associated with a specific biology. We reviewed three cases from our institution to demonstrate the variable clinical course and provide a brief review on this disease entity.

References

Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma relat-ed to serous borderline tumors. Am J Surg Pathol. 1996; 20(11): 1319-1330.

Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. 4th ed; MD, USA: WHO, IARC; 2014: 6.

Köbel M, Kalloger SE, Lee S, et al. Biomarker-based ovar-ian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomark-ers Prev. 2013; 22(10): 1677-1686. doi: 10.1158/1055-9965. EPI-13-0391

Sieh W, Köbel M, Longacre TA, et al. Hormone-receptor ex-pression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013; 14(9): 853-862. doi: 10.1016/S1470-2045(13)70253-5

Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcino-mas. Int J Gynecol Pathol. 2010; 29(3): 203-211. doi: 10.1097/ PGP.0b013e3181c042b6

Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5): 1511-1518. doi: 10.1016/S0002- 9440(10)63708-X

Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003; 95(6): 484-486. doi: 10.1093/jnci/95.6.484

Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carci-noma of the ovary. J Pathol. 2010; 221(1): 49-56. doi: 10.1002/ path.2696

Altman AD, Nelson GS, Ghatage P, et al. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Mod Pathol. 2013; 26(9): 1255-1263. doi: 10.1038/modpathol.2013.55

Malpica A, Deavers MT, Lu K, et al. Grading ovarian se-rous carcinoma using a two-tier system. Am J Surg Pathol. 2004; 28(4): 496-504.

Helland A, Anglesio MS, George J, et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggres-sive high-grade serous ovarian cancers. PLoS One. 2011; 6(4): e18064. doi: 10.1371/journal.pone.0018064

Jones S, Wang TL, Kurman RJ, et al. Low-grade serous car-cinomas of the ovary contain very few point mutations. J Pathol. 2012; 226(3): 413-420. doi: 10.1002/path.3967

Tsang YT, Deavers MT, Sun CC, et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumor are associated with recurrent low-grade serous carcinoma. J Pathol. 2013; 231(4): 449-456. doi: 10.1002/path.4252

Diaz-Padilla I, Malpica AL, Minig L, Chiva LM, Gershen-son DM, Gonzalez-Martin A. Ovarian low-grade serous carci-noma: a comprehensive update. Gynecol Oncol. 2012; 126(2): 279-285. doi: 10.1016/j.ygyno.2012.04.029

Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR. Ovarian serous tumors of low malignant po-tential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol. 2005; 29(6): 707-723.

May T, Virtanen C, Sharma M, et al. Low malignant poten-tial tumors with micropapillary features are molecularly simi-lar to low-grade serous carcinoma of the ovary. Gynecol Oncol. 2010; 117(1): 9-17. doi: 10.1016/j.ygyno.2010.01.006

Silva EG, Deavers MT, Malpica A. Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganized orphan papil-lae. Int J Gynecol Pathol. 2010; 29(6): 507-512. doi: 10.1097/ PGP.0b013e3181e31f74

Djordjevic B, Malpica A. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcino-ma. Am J Surg Pathol. 2012; 36(7): 955-963. doi: 10.1097/ PAS.0b013e31825793e1

Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional pa-clitaxel and carboplatin for treatment of advanced epithelial ovar-ian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013; 14(10): 1020-1026. doi: 10.1016/S1470-2045(13)70363-2

Schmeler KM, Sun CC, Bodurka DC, et al. Neoadjuvant che-motherapy for low-grade serous carcinoma of the ovary or peri-toneum. Gynecol Oncol. 2008; 108(3): 510-514. doi: 10.1016/j. ygyno.2007.11.013

Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemore-sistant. Gynecol Oncol. 2009; 114(1): 48-52. doi: 10.1016/j. ygyno.2009.03.001

Gershenson DM, The life and times of low-grade serous car-cinoma of the ovary. Am Soc Clin Oncol Educ Book. 2013; 195- 199. doi: 10.1200/EdBook_AM.2013.33.e195

Gershenson DM, Sun CC, Lu KH, et al. Clinical behav-ior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006; 108(2): 361-368. doi: 10.1097/01. AOG.0000227787.24587.d1

Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Den-mark 1978-2006. Gynecol Oncol. 2012; 125(3): 655-660. doi: 10.1016/j.ygyno.2012.02.028

Ali RH, Kalloger SE, Santos JL, Swenerton KD, Gilks CB. Stage II to IV low-grade serous carcinoma of the ovary is associat-ed with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. Int J Gynecol Pathol. 2013; 32(6): 529-535. doi: 10.1097/PGP.0b013e31827630eb

Köbel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma his-totype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 2014; 64: 1004-1013. doi: 10.1111/his.12349

Gershenson DM, Sun CC, Iyer RB, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peri-toneum. Gynecol Oncol. 2012; 125(3): 661-666. doi: 10.1016/j. ygyno.2012.02.037

Escobar J, Klimowicz AC, Dean M, et al. Quantifica-tion of ER/PR expression in ovarian low-grade serous carci-noma. Gynecol Oncol. 2013; 128(2): 371-376. doi: 10.1016/j. ygyno.2012.10.013

Wong KK, Lu KH, Malpica A, et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol. 2007; 26(4): 404-409.

Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lan-cet Oncol. 2013; 14(2): 134-140. doi: 10.1016/S1470-2045- (12)70572-7

FaderAN, Java J, KrivakTC, et al.The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian car-cinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2013; 132(3): 560-565. doi: 10.1016/j.ygyno.2013.11.016

Downloads

Published

2015-05-11

How to Cite

Khadija Warfa, Martin Köbel, Prafull Ghatage, & Gregg Nelson. (2015). Low-Grade Serous Carcinoma – The Clinical Challenge. Gynecology and Obstetrics Research, 2(1), 35–40. https://doi.org/10.17140/GOROJ-2-108

Issue

Vol. 2 No. 1 (2015): Volume 2 Issue 1 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Gynecology and Obstetrics Research (GOR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.